Clinical trials: China
Paroxysmal Nocturnal Hemoglobinuria
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
This is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in adult participants with paraxysmal noturnal…
- Trial name
- Soliris (NCT05886244)
- Testing
- Eculizumab
- Where
- 7 sites in China
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with…
- Trial name
- NCT01214239
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Osteoarthritis
A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China
The purpose of this study is to assess the efficacy and safety of duloxetine once daily compared with placebo on the reduction of pain due to osteoarthritis (OA) in knee or hip in participants in China.
- Trial name
- NCT01931475
- Testing
- Duloxetine
- Where
- 12 sites in China
- Volunteers
- 407 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China
The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.
- Trial name
- NCT03710083
- Testing
- Guardian™ Sensor (3)
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Chronic Hepatitis C
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
The purpose of this study is to evaluate the efficacy and safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination with Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1.
- Trial name
- NCT03020082
- Testing
- Danoprevir, Ritonavir, peginterferon alfa-2a
- Volunteers
- 141 people
- Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
Vaccine Refusal
Optimizing HPV Vaccine Introduction in Shanghai, China
Within low, middle, and upper income countries, low vaccine coverage results from both obstacles to vaccine access and low confidence in vaccine programs.
- Trial name
- NCT03972813
- Testing
- Broadened information about cancers, Information about STDs, Information about infectious disease
- Where
- China
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Ankylosing Spondylitis
Efficacy and Safety of Adalimumab in Adult Chinese Subjects With Active Ankylosing Spondylitis
Study of the efficacy and safety of adalimumab compared with placebo in adult Chinese participants with ankylosing spondylitis (AS) who have had an inadequate response to or who are intolerant to one or more nonsteroidal…
- Trial name
- NCT01114880
- Testing
- adalimumab
- Where
- 9 sites in China
- Volunteers
- 344 people
- Sponsor
- Abbott
Chronic Cough
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China Extension
The primary objective of this study will be to evaluate the efficacy of gefapixant (MK-7264) in reducing cough frequency as measured over a 24-hour period.
- Trial name
- NCT04525885
- Testing
- Gefapixant 45 mg twice daily (BID), Gefapixant 15 mg BID, Gefapixant 45 mg BID
- Where
- 8 sites in China
- Volunteers
- 161 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
The purpose of this study is to assess the benefit of immediate hormonal treatment after Radical Prostatectomy in Chinese and Russian patients with high risk prostate cancer.
- Trial name
- PRIORITI (NCT01753297)
- Testing
- Triptorelin 11.25 mg
- Where
- 18 sites in China, Russia
- Volunteers
- 226 people
- Sponsor
- Ipsen
Pre-Exposure Prophylaxis
The Blued+ Combination HIV Prevention Pilot Study in China
The proposed research includes a longitudinal pilot study to assess the feasibility and acceptability of Blued+. This combination HIV prevention intervention will integrate a combination package of HIV prevention services into…
- Trial name
- Blued+ (NCT06647173)
- Testing
- Blued+ Service Platform
- Where
- China
- Volunteers
- 423 people, healthy volunteers welcome
- Sponsor
- Emory University
Atypical Hemolytic Uremic
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
This is a Phase 3b, open-label, single-arm, multicenter study to evaluate the efficacy and safety of eculizumab in participants with atypical hemolytic uremic syndrome (aHUS) in China
- Trial name
- Soliris (NCT05876351)
- Testing
- Eculizumab
- Where
- 6 sites in China
- Volunteers
- 25 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Benign Prostatic Hyperplasia (BPH)
To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China
A real world study to evaluate the feasibility, preliminary safety and performance of Rezūm system in BPH treatment in China Rezūm RWS study
- Trial name
- NCT04823221
- Testing
- Rezūm System
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Breast Neoplasms
Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Aromasin® (Exemestane) was approved in China for adjuvant treatment of postmenopausal women with estrogen receptor (ER) positive early invasive breast cancer who have received 2-3 years of tamoxifen \& are switched to Aromasin®…
- Trial name
- NCT01176916
- Testing
- Aromasin (exemestane)
- Where
- 53 sites in China
- Volunteers
- 564 people
- Sponsor
- Pfizer
Lung Diseases, Interstitial
A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis
This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old.
- Trial name
- NCT05065190
- Testing
- Nintedanib
- Where
- 16 sites in China
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea
- Trial name
- POETYK-PSO-3 (NCT04167462)
- Testing
- BMS-986165
- Where
- 34 sites in China, South Korea and 1 more
- Volunteers
- 220 people
- Sponsor
- Bristol-Myers Squibb
HIV-1 Infections
Clinical, Virological and Safety Outcomes of a Lopinavir/Ritonavir-Based Regimen in HIV-1 Infected Patients in Routine Clinical Use in China
This post-marketing observational study is conducted for obtaining data on clinical, biological and virological outcomes, compliance and tolerability of using a lopinavir/ritonavir (LPV/r) -containing regimen for the treatment of…
- Trial name
- NCT01074931
- Testing
- Lopinavir/ritonavir (Kaletra)
- Where
- 5 sites in China
- Volunteers
- 98 people
- Sponsor
- Abbott
Hepatitis C
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV) Dual regimen (= Daclatasvir + Asunaprevir)…
- Trial name
- NCT01995266
- Testing
- Asunaprevir, Daclatasvir
- Where
- 38 sites in China, South Korea and 1 more
- Volunteers
- 218 people
- Sponsor
- Bristol-Myers Squibb
Osteoporosis, Postmenopausal
A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264)
This study will evaluate whether the once weekly administration of the combination tablet alendronate/vitamin D3 (FOSAMAX PLUS) will increase lumbar spine bone mineral density (BMD) more than the daily use of calcitriol.
- Trial name
- NCT01350934
- Testing
- alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus), Calcitriol, Calcium 500 mg
- Volunteers
- 219 people
- Sponsor
- Organon and Co
Pulmonary Disease, Chronic Obstructive
Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China
This is a non-drug interventional cohort study, which aims to investigate the clinical, radiological and biological factors associated with disease progression in COPD in China.
- Trial name
- NCT04853225
- Testing
- Prospective observational cohort study
- Where
- 41 sites in China
- Volunteers
- 2,005 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Gestational Diabetes Mellitus
Randomized Translational Study to Examine the Effects of Shared Care in Management of Gestational Diabetes
Research question (s)/hypothesis: 1. . The effectiveness of the shared care management of gestational diabetes mellitus; 2. . The cost-effectiveness of the shared care management; 3. . Its sustainability
- Trial name
- NCT01565564
- Testing
- Shared glycaemic control care within the local three-tier's antenatal care network
- Where
- China
- Volunteers
- 948 people
- Sponsor
- Tianjin Women and Children's Health Center